Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.52 |
| ▸ | REN | P00797 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PEPD | P12955 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL239406 | 1.00 | ACE (0.52) | ACERENKDM4EF2LMNA | |
| SCHEMBL12598148 | 1.00 | ACE (0.52) | ACERENKDM4EF2LMNA | |
| SCHEMBL12567110 | 1.00 | ACE (0.52) | ACERENKDM4EF2LMNA | |
| SCHEMBL239407 | 1.00 | ACE (0.52) | ACERENKDM4EF2LMNA | |
| SCHEMBL15692916 | 0.96 | ACE (0.48) | ACERENKDM4EF2LMNA | |
| SCHEMBL21641824 | 0.89 | ACE (0.50) | ACERENKDM4EF2LMNA | |
| SCHEMBL21641823 | 0.89 | ACE (0.50) | ACERENKDM4EF2LMNA | |
| SCHEMBL18913820 | 0.89 | ACE (0.50) | ACERENKDM4EF2LMNA | |
| SCHEMBL12566960 | 0.89 | DPP4 (0.51) | NR1I2ABCB11CYP3A4CYP2C9OPRK1 | |
| SCHEMBL12599485 | 0.89 | CYP3A4 (0.49) | PEPDNR1I2ABCB11CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006070012-A1 | AGENTS USEFUL IN TREATING INFLAMMATORY BOWEL DISEASE | INGENIUM PHARMACEUTICALS AG (DE) | 2006-07-06 | — | — | WO | claimed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20210053981-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
| EP-3778606-A2 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2021-02-17 | — | — | EP | disclosed |
| WO-2020219808-A1 | DICARBAMATE INHIBITORS OF NS5A FOR TREATMENT OF HEPATITIS C VIRUS INFECTIONS AND RELATED DISEASES | BETA PHARMA, INC. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020219808-A1 | DICARBAMATE INHIBITORS OF NS5A FOR TREATMENT OF HEPATITIS C VIRUS INFECTIONS AND RELATED DISEASES | BETA PHARMA, INC. (US) | 2020-10-29 | — | — | WO | disclosed |
| US-10807990-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2020-10-20 | — | — | US | disclosed |
| US-10800789-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2020-10-13 | — | — | US | disclosed |
| EP-3699176-A2 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20110092415-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-04-21 | — | — | US | disclosed |
| US-20100317568-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-12-16 | — | — | US | disclosed |
| US-20030087831-A1 | 1,3,4-Oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-05-08 | — | — | US | disclosed |
| EP-1234834-A1 | 1,3,4-OXADIAZOLIN-2-ONE DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-08-28 | — | — | EP | disclosed |
| US-6054593-A | Proline derivatives | ZENECA LIMITED (GB) | 2000-04-25 | — | — | US | disclosed |
| US-6048889-A | Proline derivatives | ZENECA LIMITED (GB) | 2000-04-11 | — | — | US | disclosed |
| US-5808097-A | OXIDATION OF THE CORRESPONDING HYDROXY COMPOUND | ZENECA LIMITED (GB) | 1998-09-15 | — | — | US | disclosed |
| EP-0808327-A1 | PROLINE DERIVATIVES USEFUL AS INHIBITORS OF HUMAN LEUKOCYTE ELASTASE | ZENECA LIMITED (GB) | 1997-11-26 | — | — | EP | disclosed |
| US-5686628-A | Proline derivatives | ZENECA LTD. (GB) | 1997-11-11 | — | — | US | disclosed |
| WO-1996023812-A1 | PROLINE DERIVATIVES USEFUL AS INHIBITORS OF HUMAN LEUKOCYTE ELASTASE | ZENECA LIMITED (GB) | 1996-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317568-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | ACE 256/4885REN 2184/4885KDM4E 2318/4885 |
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | ACE 256/4885REN 2184/4885KDM4E 2318/4885 |
| US-20030087831-A1 | 1,3,4-Oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient | SERPINB1, ELANE, MMP8 | ACE 1482/4885REN 562/4885KDM4E 4556/4885 |
| US-20110092415-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | ACE 256/4885REN 2184/4885KDM4E 2318/4885 |
| US-10807990-B2 | Antiviral compounds | MAVS, EIF2AK2, SARS1 | ACE 133/4885REN 3159/4885KDM4E 3215/4885 |
| US-10800789-B2 | Antiviral compounds | MAVS, EIF2AK2, SARS1 | ACE 133/4885REN 3159/4885KDM4E 3215/4885 |
| US-20210053981-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | ACE 133/4885REN 3159/4885KDM4E 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.